Gilead Sciences (GILD) 70.01 $GILD Most active
Post# of 273317
Posted On: 04/08/2014 7:16:09 PM
Gilead Sciences (GILD) 70.01 $GILD
Most active Nasdaq-traded stocks
AP - 46 mins ago
NEW YORK (AP) — A look at Nasdaq 10 most-active stocks at the close of trading:
Final Glance: Biotechnology companies
AP - 47 mins ago
NEW YORK (AP) — Shares of some top biotechnology companies were down at the close of trading:
Pipeline Update from Idenix - Analyst Blog
Zacks Equity Research - Zacks Investment Research - 2 hrs 20 mins ago
Idenix's nucleotide polymerase inhibitor candidate, IDX21437, showed potent antiviral activity in patients suffering from hepatitis C virus (HCV) infection.
Watch for Gilead Sciences to Potentially Rebound After Falling 3.07% Yesterday
Comtex SmarTrend(R) - 2 hrs 34 mins ago
Gilead Sciences (NASDAQ:GILD) traded in a range yesterday that spanned from a low of $69.28 to a high of $71.71. Yesterday, the shares fell 3.1%, which took the trading range below the 3-day low of $70.72 on volume of 25.2 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
Nike Sprints Higher as the Dow Dips Again
Dan Carroll, The Motley Fool - Motley Fool - Tue Apr 08, 1:39PM CDT
While stocks have bounced back from yesterday's big losses as the markets approach earnings season again, one index is heading down again. As of 2:35 p.m. EDT, the Dow Jones Industrial Average was just under breakeven, with blue-chip member stocks...
Midday Glance: Biotechnology companies
AP - Tue Apr 08, 12:16PM CDT
NEW YORK (AP) — Shares of some top biotechnology companies are mixed at 1 p.m.:
FDA Target Date for Gilead's HCV Candidate - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Apr 08, 10:30AM CDT
Gilead is looking to bring a fixed-dose combination of Sovaldi and ledipasvir into the market for treating HCV.
Healthcare Investors Suffering Losses While Drug-Pricing War Rages
at The Street - Tue Apr 08, 10:23AM CDT
The latest salvo was lobbed Tuesday by pharmacy benefits manager Express Scripts against Gilead Sciences and its $1,000-per-day hepatitis C pill Sovaldi. Express Scripts says the U.S. healthcare system can't afford Sovaldi so it wants to form a...
Jim Cramer's Stop Trading: GILD ESRX
at The Street - Tue Apr 08, 9:59AM CDT
In the battle between Gilead and Express Scripts over the cost of hepatitis C pill Sovaldi, Gilead wins, Cramer asserts.
Early Glance: Biotechnology companies
AP - Tue Apr 08, 9:43AM CDT
NEW YORK (AP) — Shares of some top biotechnology companies are mixed at 10 a.m.:
Encouraging Results from Pfizer's Palbociclib - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Apr 08, 9:40AM CDT
Pfizer announced positive detailed results from the phase II study on palbociclib.
Watch for Shares of Gilead Sciences (GILD) to Approach Support at $69.22
Comtex SmarTrend(R) - Tue Apr 08, 9:02AM CDT
Gilead Sciences (NASDAQ:GILD) has opened bearishly below the pivot of $72.23 today and has reached the first level of support at $70.72. Analysts will be watching for a cross of the next downside pivot targets of $69.22 and $66.21.
MannKind vs. Idenix: Better Biotech Buy
David Williamson, The Motley Fool - Motley Fool - Mon Apr 07, 6:17PM CDT
In this video after a big day in the biotech sector, Motley Fool health-care analyst David Williamson takes investors through today's big winner and loser. Idenix is the winner for the day, up 10% after posting solid results in a...
A $1 Trillion Drug Market?
Brian Orelli, The Motley Fool - Motley Fool - Mon Apr 07, 5:30PM CDT
At the Barclays Global Healthcare Conference 2014 last month, Christopher Anzalone, president and CEO of Arrowhead Research put up a slide suggesting that its hepatitis B drug would treat a $1 trillion market "even under conservative pricing...
Tweet of the Week: Big Biotech Dominates Industry Gains
Brian Orelli and Max Macaluso, The Motley Fool - Motley Fool - Mon Apr 07, 4:25PM CDT
This week's tweet comes from Bruce Booth (@LifeSciVC), who points out analysts at Bernstein concluded that just six companies contributed to 77% of the increase in value of the biotech sector over the past three years. There's no doubt that Amgen...
Momentum Slide to Continue for Netflix, Facebook? - Analyst Blog
Swarup Gupta - Zacks Investment Research - Mon Apr 07, 12:21PM CDT
Momentum stocks may soon bounce back, but for now earnings hold the key.
Most active Nasdaq-traded stocks
AP - 46 mins ago
NEW YORK (AP) — A look at Nasdaq 10 most-active stocks at the close of trading:
Final Glance: Biotechnology companies
AP - 47 mins ago
NEW YORK (AP) — Shares of some top biotechnology companies were down at the close of trading:
Pipeline Update from Idenix - Analyst Blog
Zacks Equity Research - Zacks Investment Research - 2 hrs 20 mins ago
Idenix's nucleotide polymerase inhibitor candidate, IDX21437, showed potent antiviral activity in patients suffering from hepatitis C virus (HCV) infection.
Watch for Gilead Sciences to Potentially Rebound After Falling 3.07% Yesterday
Comtex SmarTrend(R) - 2 hrs 34 mins ago
Gilead Sciences (NASDAQ:GILD) traded in a range yesterday that spanned from a low of $69.28 to a high of $71.71. Yesterday, the shares fell 3.1%, which took the trading range below the 3-day low of $70.72 on volume of 25.2 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
Nike Sprints Higher as the Dow Dips Again
Dan Carroll, The Motley Fool - Motley Fool - Tue Apr 08, 1:39PM CDT
While stocks have bounced back from yesterday's big losses as the markets approach earnings season again, one index is heading down again. As of 2:35 p.m. EDT, the Dow Jones Industrial Average was just under breakeven, with blue-chip member stocks...
Midday Glance: Biotechnology companies
AP - Tue Apr 08, 12:16PM CDT
NEW YORK (AP) — Shares of some top biotechnology companies are mixed at 1 p.m.:
FDA Target Date for Gilead's HCV Candidate - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Apr 08, 10:30AM CDT
Gilead is looking to bring a fixed-dose combination of Sovaldi and ledipasvir into the market for treating HCV.
Healthcare Investors Suffering Losses While Drug-Pricing War Rages
at The Street - Tue Apr 08, 10:23AM CDT
The latest salvo was lobbed Tuesday by pharmacy benefits manager Express Scripts against Gilead Sciences and its $1,000-per-day hepatitis C pill Sovaldi. Express Scripts says the U.S. healthcare system can't afford Sovaldi so it wants to form a...
Jim Cramer's Stop Trading: GILD ESRX
at The Street - Tue Apr 08, 9:59AM CDT
In the battle between Gilead and Express Scripts over the cost of hepatitis C pill Sovaldi, Gilead wins, Cramer asserts.
Early Glance: Biotechnology companies
AP - Tue Apr 08, 9:43AM CDT
NEW YORK (AP) — Shares of some top biotechnology companies are mixed at 10 a.m.:
Encouraging Results from Pfizer's Palbociclib - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Apr 08, 9:40AM CDT
Pfizer announced positive detailed results from the phase II study on palbociclib.
Watch for Shares of Gilead Sciences (GILD) to Approach Support at $69.22
Comtex SmarTrend(R) - Tue Apr 08, 9:02AM CDT
Gilead Sciences (NASDAQ:GILD) has opened bearishly below the pivot of $72.23 today and has reached the first level of support at $70.72. Analysts will be watching for a cross of the next downside pivot targets of $69.22 and $66.21.
MannKind vs. Idenix: Better Biotech Buy
David Williamson, The Motley Fool - Motley Fool - Mon Apr 07, 6:17PM CDT
In this video after a big day in the biotech sector, Motley Fool health-care analyst David Williamson takes investors through today's big winner and loser. Idenix is the winner for the day, up 10% after posting solid results in a...
A $1 Trillion Drug Market?
Brian Orelli, The Motley Fool - Motley Fool - Mon Apr 07, 5:30PM CDT
At the Barclays Global Healthcare Conference 2014 last month, Christopher Anzalone, president and CEO of Arrowhead Research put up a slide suggesting that its hepatitis B drug would treat a $1 trillion market "even under conservative pricing...
Tweet of the Week: Big Biotech Dominates Industry Gains
Brian Orelli and Max Macaluso, The Motley Fool - Motley Fool - Mon Apr 07, 4:25PM CDT
This week's tweet comes from Bruce Booth (@LifeSciVC), who points out analysts at Bernstein concluded that just six companies contributed to 77% of the increase in value of the biotech sector over the past three years. There's no doubt that Amgen...
Momentum Slide to Continue for Netflix, Facebook? - Analyst Blog
Swarup Gupta - Zacks Investment Research - Mon Apr 07, 12:21PM CDT
Momentum stocks may soon bounce back, but for now earnings hold the key.
(0)
(0)